Document Detail


Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension.
MedLine Citation:
PMID:  22853986     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Pulmonary arterial hypertension (PAH) is a disease characterized by increased pulmonary pressures and chronic right heart failure. Therapies for moderate and severe PAH include subcutaneous (SQ) and intravenous (IV) prostanoids that improve symptoms and quality of life. However, treatment compliance can be limited by severe side effects and complications related to methods of drug administration. Inhaled prostanoids, which offer the advantage of direct delivery of the drug to the pulmonary circulation without need for invasive approaches, may serve as an alternative for patients unable to tolerate SQ/IV therapy. In this retrospective cohort study we collected clinical, hemodynamic, and functional data from 18 clinically stable patients with World Health Organization group I PAH seen in 6 large national PAH centers before and after transitioning to inhaled treprostinil from IV/SQ prostanoids. Before transition 15 patients had been receiving IV or SQ treprostinil (mean dose 73 ng/kg/min) and 3 patients had been on IV epoprostenol (mean dose 10 ng/kg/min) for an average duration of 113 ± 80 months. Although most patients who transitioned to inhaled treprostinil demonstrated no statistically significant worsening of hemodynamics or 6-minute walk distance, a minority demonstrated worsening of New York Heart Association functional class over a 7-month period. In conclusion, although transition of patients from IV/SQ prostanoids to inhaled treprostinil appears to be well tolerated in clinically stable patients, they should remain closely monitored for signs of clinical decompensation.
Authors:
Vinicio A de Jesus Perez; Erica Rosenzweig; Lewis J Rubin; David Poch; Abubakr Bajwa; Myung Park; Mohit Jain; Robert C Bourge; Kristina Kudelko; Edda Spiekerkoetter; Juliana Liu; Andrew Hsi; Roham T Zamanian
Related Documents :
2151316 - Inflammatory bowel disease and serum beta-n-acetylhexosaminidase.
18422816 - Relapses of inflammatory bowel disease during pregnancy: in-hospital management and bir...
11923606 - Increased adhesion molecule expression in serosal fibroblasts isolated from patients wi...
2766906 - Cyclosporin a treatment in inflammatory bowel disease.
19214296 - Usefulness of clinical and electrocardiographic data for predicting adverse cardiac eve...
3890526 - A renal biopsy study of lupus nephropathy in the united states and korea.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-30
Journal Detail:
Title:  The American journal of cardiology     Volume:  -     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-8-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier Inc.
Affiliation:
Stanford University, Stanford, California.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Percutaneous balloon-expandable covered stent implantation for treatment of traumatic aortic injury ...
Next Document:  Updated US Department of Agriculture Food Patterns Meet Goals of the 2010 Dietary Guidelines.